Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the patient is either at risk of developing a cholesterol-associated tumor or already exhibits a cholesterol-associated tumor. Formulations of ezetimibe are also provided for the prevention or treatment of a cholesterol-associated tumor further comprising at least one other anticancer agent. An article of manufacture is also provided which comprises a container, instructions, and a composition, wherein the composition comprises a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe or its phenolic glucuronide, and the instructions are for the administration of the composition for the prevention or treatment of a cholesterol-associated tumor.
1. A composition for the treatment of a cholesterol-associated tumor comprising a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor and at least one other anticancer agent selected from the group consisting of a steroidal antiandrogen, a non steroidal antiandrogen, and estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog.
2. The composition according to claim 1 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe.
3. The composition according to claim 2 wherein the non-steroidal antiandrogen is selected from the group consisting of finasteride (PROSCAR®), flutamide (4′-nitro-3′-trifluorormethyl isobutyranilide), bicalutamide (CASODEX®), and nilutamide).
4. The composition according to claim 2 wherein the SERM is selected from the group consisting of tamoxifen, raloxifene, droloxifene, and idoxifene.
5. The composition according to claim 2 wherein the taxane is selected from the group consisting of paclitaxel (TAXOL®), and docetaxel (TAXOTERE®).
6. The composition according to claim 2 wherein the LHRH analog is selected from the group consisting of goserelin acetate (ZOLADEX®), and leuprolide acetate (LUPRON®).
7. An article of manufacture comprising a container, instructions, and a composition, wherein the composition comprises a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor and at the least one other anticancer agent, and the instructions are for the administration of the composition for the treatment of a cholesterol-associated tumor, wherein at least one other anticancer agent is selected from the group consisting of a steroidal antiandrogen, a non-steroidal antiandrogen, an estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog.
8. The article of manufacture according to claim 7 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and/or at least one pharmacologically active analog thereof.
9. The article of manufacture according to claim 8 wherein the instructions are for the administration of the composition for the treatment of a tumor selected from the group consisting of prostatic hypertrophy (prostate tumor), breast tumor endometrial tumor, and colon tumor.
10. A method of treatment of a cholesterol-associated tumor comprising administrating a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor to a patient wherein the patient exhibits a cholestrol-associated tumor.
11. The method of treatment of a cholestrerol-associated tumor according to claim 10 wherein the azetidinone-based cholesterol absorption inhibitor is selected from the group consisting of ezetimibe, SCH 48461 and SCH 58053.
12. The method of treatment of a cholesterol-associated tumor according to claim 11 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe or a stereoisomeric mixture thereof, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomer thereof, or a prodrug of such compound, mixture or isomer thereof, or a pharmaceutically acceptable salt of the compound, mixture, isomer or prodrug.
13. The method of treatment of a cholestereol-associated tumor according to claim 10 wherein the azetidinone-based cholesterol absorption inhibitor is selected from the group consisting of ezetimibe, the phenolic glucuronide of ezetimibe, SCH 48461 and SCH 58053.
14. The method of treatment of a cholesterol-associated tumor according to claim 10 wherein the cholesterol-associated tumor is selected from the group consisting of benign prostatic hypertrophy, benign breast tumor, benign endometrial tumor, and benign colon tumor.
15. The method of treatment of a cholesterol-associated tumor according to claim 10 wherein the cholesterol-associated tumor is selected from the group consisting of malignant prostate tumor, breast cancer tumor, endometrial cancer tumor, and colon cancer tumor.
16. The method of treatment of a cholesterol-associated tumor according to claim 14 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and/or at least one pharmacologically active analog thereof.
17. The method of treatment of a cholesterol-associated tumor according to claim 15 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and/or at least one pharmacologically active analog thereof.
18. The method of treatment of a cholesterol-associated tumor according to claim 16 wherein a therapeutically effective amount is between 0.1 to 30 mg/kg of body weight daily.
19. The method of treatment of a cholesterol-associated tumor according to claim 17 wherein a therapeutically effective amount is between 0.1 to 30 mg/kg of body weight daily.
20. A method of treatment of a cholesterol-associated tumor comprising co-administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor and at least one other anticancer agent to a patient wherein the patient exhibits a cholestrol-associated tumor.
21. The method of treatment according to claim 20 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and its analogs.
22. The method of treatment according to claim 21 wherein at least one other anticancer agent is selected from the group consisting of a steroidal antiandrogen, a non steroidal antiandrogen, an estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog.
23. The method of treatment according to claim 22 wherein the non steroidal antiandrogen is selected from the group consisting of finasteride (PROSCAR®), flutamide (4′-nitro-3′-trifluoromiethyl isobutyranilide), bicalutamide (CASODEX®), and nilutamide.
24. The method of treatment according to claim 22 wherein the SERM is selected from the group consisting of tamoxifen, raloxifene, droloxifene, and idoxifene.
25. The method of treatment according to claim 22 wherein the taxane is selected from the group consisting of paclitaxel (TAXOL®), and docetaxel (TAXOTERE®).
26. The method of treatment according to claim 22 wherein the LHRH analog is selected from the group consisting of goserelin acetate (ZOLADEX®), and leuprolide acetate (LUPRON®).